Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial

ABSTRACT Aims/Introduction Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabete...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes investigation 2022-03, Vol.13 (3), p.489-500
Main Authors: Hata, Shinnosuke, Nakajima, Hanako, Hashimoto, Yoshitaka, Miyoshi, Tomoki, Hosomi, Yukako, Okamura, Takuro, Majima, Saori, Nakanishi, Naoko, Senmaru, Takafumi, Osaka, Takafumi, Okada, Hiroshi, Ushigome, Emi, Hamaguchi, Masahide, Asano, Mai, Yamazaki, Masahiro, Fukui, Michiaki
Format: Article
Language:English
Subjects:
Aged
Antidiabetics
Bifidobacterium bifidum
Constipation
Deoxyribonucleic acid
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diarrhea
Dietary supplements
Disease
DNA
Double-Blind Method
Gastrointestinal Diseases - etiology
Genetic testing
Hemoglobin
Humans
Informed consent
Intestinal microflora
Laboratories
Metformin
Metformin - therapeutic use
Microbiota
Middle Aged
Original
Polymerase chain reaction
Probiotics
Probiotics - therapeutic use
Taxonomy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Aims/Introduction Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. Materials and methods In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t‐test. Results The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P 
ISSN:2040-1116
2040-1124
2040-1124
DOI:10.1111/jdi.13698